The Impact of Circulating Tumor Cells on Venous Thromboembolism and Cardiovascular Events in Bladder Cancer Patients Treated with Radical Cystectomy.
bladder cancer
cardiovascular event
circulating tumor cell
radical cystectomy
urothelial carcinoma
venous thromboembolism
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
28 Oct 2020
28 Oct 2020
Historique:
received:
07
10
2020
revised:
22
10
2020
accepted:
26
10
2020
entrez:
31
10
2020
pubmed:
1
11
2020
medline:
1
11
2020
Statut:
epublish
Résumé
Cancer is a relevant risk factor for venous thromboembolism (VTE). Circulating tumor cells (CTC) are associated with an increased risk of VTE in breast cancer. In addition, circulating cell-free nucleic acids have been associated with cardiovascular events (CVE). To investigate the association of CTC status and the risk of VTE as well as CVE in urothelial carcinoma of the bladder (UCB) patients treated with radical cystectomy (RC). We collected data of 189 UCB patients treated with RC at our institution. Blood samples were acquired preoperatively and analyzed for CTC using the CellSearch CTC were present in 43 patients (22.8%). Overall, six patients experienced VTE (3.2%) and eight patients (4.2%) experienced CVE. There was no association of VTE or CVE according to CTC status. In total, 168 patients (89%) experienced a total of 801 complications, of which the majority was classified as "minor" (CDC grade ≤ IIIa; 79%). There was no association between CTC status and any grade of a complication or CCI The overall rate of VTE and CVE was low in our study. Presence of CTC was neither associated with an increased risk of VTE nor CVE in UCB patients treated with RC. According to this study, CTC are not a qualified biomarker for individualized thromboprophylaxis management in these patients.
Sections du résumé
BACKGROUND
BACKGROUND
Cancer is a relevant risk factor for venous thromboembolism (VTE). Circulating tumor cells (CTC) are associated with an increased risk of VTE in breast cancer. In addition, circulating cell-free nucleic acids have been associated with cardiovascular events (CVE).
OBJECTIVE
OBJECTIVE
To investigate the association of CTC status and the risk of VTE as well as CVE in urothelial carcinoma of the bladder (UCB) patients treated with radical cystectomy (RC).
METHODS
METHODS
We collected data of 189 UCB patients treated with RC at our institution. Blood samples were acquired preoperatively and analyzed for CTC using the CellSearch
RESULTS
RESULTS
CTC were present in 43 patients (22.8%). Overall, six patients experienced VTE (3.2%) and eight patients (4.2%) experienced CVE. There was no association of VTE or CVE according to CTC status. In total, 168 patients (89%) experienced a total of 801 complications, of which the majority was classified as "minor" (CDC grade ≤ IIIa; 79%). There was no association between CTC status and any grade of a complication or CCI
CONCLUSIONS
CONCLUSIONS
The overall rate of VTE and CVE was low in our study. Presence of CTC was neither associated with an increased risk of VTE nor CVE in UCB patients treated with RC. According to this study, CTC are not a qualified biomarker for individualized thromboprophylaxis management in these patients.
Identifiants
pubmed: 33126664
pii: jcm9113478
doi: 10.3390/jcm9113478
pmc: PMC7692134
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Hosp Pract (1995). 2011 Apr;39(2):7-17
pubmed: 21576893
Eur Heart J. 2019 Dec 21;40(48):3889-3897
pubmed: 31761945
Eur Urol. 2020 Apr 29;:
pubmed: 32360052
Eur Urol. 2009 Jan;55(1):164-74
pubmed: 18675501
Ann Surg. 2013 Jul;258(1):1-7
pubmed: 23728278
Eur Urol. 2012 Apr;61(4):810-7
pubmed: 22277196
Biomol Detect Quantif. 2019 Mar 18;17:100087
pubmed: 30923679
BJU Int. 2017 Jun;119(6):854-861
pubmed: 28182321
Transl Androl Urol. 2017 Dec;6(6):1090-1110
pubmed: 29354496
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Biomark Med. 2018 Aug;12(8):891-905
pubmed: 30025473
Crit Rev Oncol Hematol. 2017 Jun;114:33-42
pubmed: 28477745
Ann Surg. 2009 Aug;250(2):187-96
pubmed: 19638912
Cancer Med. 2019 Jul;8(7):3447-3452
pubmed: 31091022
Eur Urol. 2020 Jan;77(1):55-65
pubmed: 31473012
Thromb Haemost. 2017 Jan 26;117(2):219-230
pubmed: 27882374
Bladder Cancer. 2018 Apr 26;4(2):139-147
pubmed: 29732385
World J Urol. 2019 Sep;37(9):1785-1799
pubmed: 30367205
Thromb Haemost. 2009 Jun;101(6):1147-55
pubmed: 19492160
Eur Urol. 2012 Apr;61(4):854-5
pubmed: 22226583
Int J Urol. 2017 Feb;24(2):130-136
pubmed: 28004432
Int J Surg. 2016 Dec;36(Pt A):249-254
pubmed: 27826047
Urol Oncol. 2016 Nov;34(11):483.e17-483.e24
pubmed: 27646875
N Engl J Med. 2014 Apr 17;370(16):1494-503
pubmed: 24679062
Urol Oncol. 2018 May;36(5):221-236
pubmed: 29530466
Int J Cancer. 2017 Jan 15;140(2):381-389
pubmed: 27668704
Br J Cancer. 2009 Dec 1;101(11):1813-6
pubmed: 19888227
Thromb Haemost. 2018 Feb;118(2):251-265
pubmed: 29378353
Nat Rev Urol. 2011 Oct 25;8(12):659-66
pubmed: 22025173
Eur Urol. 2018 Feb;73(2):242-251
pubmed: 28342641